Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.67 |
| ▸ | PI4KA | P42356 | 2/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | AHCY | P23526 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965418 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL987631 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11487766 | 0.86 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL13394189 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL14963614 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12922451 | 0.84 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL13952171 | 0.84 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12948656 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL6045649 | 0.83 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL27432827 | 0.83 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868011-B2 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | GENERAL ATOMICS (US) | 2011-01-11 | — | — | US | disclosed |
| US-7517887-B2 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | GENERAL ATOMICS (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2008-08-14 | — | — | US | disclosed |
| US-20080171049-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2008-07-17 | — | — | US | disclosed |
| US-20070207172-A1 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2007-09-06 | — | — | US | disclosed |
| US-20070129386-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2007-06-07 | — | — | US | disclosed |
| US-7196093-B2 | Reversible inhibitors of SAH hydrolase and uses thereof | GENERAL ATOMICS (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207172-A1 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | AHCY, AHCYL1, BHMT | ADORA2A 70/4885ADORA1 95/4885ADORA2B 206/4885 |
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | AHCY, AHCYL1, BHMT | ADORA2A 70/4885ADORA1 95/4885ADORA2B 206/4885 |
| US-20080171049-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | AHCY, AHCYL1, BHMT | ADORA2A 72/4885ADORA1 77/4885ADORA2B 183/4885 |
| US-20070129386-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | AHCY, AHCYL1, BHMT | ADORA2A 72/4885ADORA1 77/4885ADORA2B 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.